慢性乙型肝炎在研抗病毒新药纵览  

An overview of new antiviral drugs under research for chronic hepatitis B

作　　者：何寅武 王建华 HE Yinwu;WANG Jianhua(Guangzhou Boji Medical Biotechnology Co.,Ltd.,Guangzhou 510640,China)

机构地区：[1]广州博济医药生物技术股份有限公司,广州510640

出　　处：《临床肝胆病杂志》2020年第10期2298-2304,共7页Journal of Clinical Hepatology

摘　　要：HBV感染引起的慢性乙型肝炎是全球性的公共卫生问题,而实现慢性乙型肝炎的功能性治愈甚至完全治愈一直是药物研发人员追求的目标。目前所广泛使用的核苷(酸)类似物疗法和干扰素疗法的治愈率都不高。对目前在研的病毒进入抑制剂、衣壳抑制剂、HBsAg抑制剂、免疫调节剂以及基因编辑和细胞疗法等多种类型的抗HBV药物/疗法进行了综述,汇总分析了其临床研究结果,以明了该领域研究的最新进展和药物研发的新思路。Chronic hepatitis B caused by hepatitis B virus(HBV)infection remains a major public health problem worldwide,and functional cure and even complete cure of chronic hepatitis B are the goals pursued by drug researchers.At present,widely used nucleos(t)ide analogues and interferon therapy fail to achieve a high cure rate.This article reviews the anti-HBV drugs/therapies under research,including viral entry inhibitors,capsid inhibitors,HBsAg inhibitors,immune modulators,gene editing,and cell therapies,and summarizes related clinical research findings,so as to clarify the latest advances in this field and the new ideas in drug research and development.

关 键 词：乙型肝炎 慢性 分子靶向治疗 乙型肝炎表面抗原 

分 类 号：R512.62[医药卫生—内科学]